Clinical Trials Browser

Adenocarcinoma, Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Rectal Diseases, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01396382 2016-03-29

68Ga

Phase 2 Completed

97 enrolled 4 charts

EndocrineNET

Apudoma, Carcinoid Tumor, Adenoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01886287 2015-01-12

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Phase 2 Terminated

2 enrolled 4 charts

EndocrineNET

Diarrhea, Flushing, Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00363051 2013-05-10

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Phase 2 Completed

160 enrolled 17 charts

EndocrineGastrointestinalNET

Carcinoma, Neoplasms, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01203306 2010-09-16

XELBEVOCT

Phase 2 Unknown

42 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00953394 2009-08-06

5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

Phase 2 Completed

29 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Clinical Trials

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

P-PRRT

CABONEN

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

AveNEC

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

EVINEC

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

68Ga

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

XELBEVOCT

5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors